Press Releases

 
Press Releases
Date Title and Summary View
Mar 9, 2017 MADISON, Wis., March 09, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), (the "company"), an oncology-focused, clinical stage biotechnology company, today announces that management will host a teleconference and live webcast to report fourth quarter and year-end 2016 financial results, followed by a review of...
PDF
Mar 8, 2017 MADISON, Wis., March 08, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces it has entered into a licensing agreement with the Wisconsin Alumni Research Foundation (WARF) for intellectual property rights covering the metho...
PDF
Mar 6, 2017 MADISON, Wis., March 06, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announces today that its president and CEO, Jim Caruso, will present at the 29th Annual Roth Conference on Wednesday, March 15th at 12:30 PM PT, in the Ye...
PDF
Feb 27, 2017 MADISON, Wis., Feb. 27, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today provides an update of its Phase I clinical study of CLR 131 in patients with relapsed or refractory multiple myeloma following the previously announced successful completion ...
PDF
Feb 22, 2017 MADISON, Wis., Feb. 22, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces the successful completion of Cohort 3 and initiation of Cohort 4 in the company's Phase I clinical study of CLR 131 in patients with relapsed and refractory multipl...
PDF
Feb 13, 2017 MADISON, Wis., Feb. 13, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO CEO & Investor Conference on Monday, February 13th at 2:30 PM ET, in the Windsor Room of The Waldorf Astoria Hotel...
PDF
Feb 7, 2017 MADISON, Wis., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at the 2017 BIO CEO & Investor Conference in on Monday, February 13th at 2:00 PM ET in the Windsor ...
PDF
Jan 31, 2017
Cellectar Biosciences Announces Two Peer Reviewed Studies Demonstrating the Capabilities of the PDC Platform
Nature Reviews Clinical Oncology Online Publication and Oral Presentation at Academic Surgical Congress Further Demonstrate the Potential of PDC Delivery
MADISON, Wis., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB) (the "company"), an oncology-focused, clinical stage biotechnology company, today announces the advance online publication of an article in Nature Reviews Clinical Oncology.  In addition, the company anticipates an oral prese...
PDF
Jan 26, 2017 MADISON, Wis., Jan. 26, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused, clinical stage biotechnology company, announced today that its president and CEO, Jim Caruso, will present at NobleCon13, Noble Capital Markets' 13th Annual Investor Conference at the Boca Raton Resort and ...
PDF
Jan 24, 2017 MADISON, Wis., Jan. 24, 2017 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq:CLRB), an oncology-focused clinical stage biotechnology company, today announces that the United States Patent and Trademark Office ("USPTO") has granted patent number 9,550,002, which covers method of use for the company's lead compound, CLR 131,...
PDF
Page: FirstPrevious
3
... NextLast